ADORA2A and COVID-19: Thus, the contrasting evidence that A2AR properties seems unrelated to the severity of COVID-19 whereas exogenously added agonists provide a clinical benefit [35,36] is suggestive that the major modification in the adenosine system associated with COVID-19 might be the availability of extracellular adenosine.